Literature DB >> 24167659

Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor.

Srinivas Duggineni1, Sayantan Mitra, Ilaria Lamberto, Xiaofeng Han, Yan Xu, Jing An, Elena B Pasquale, Ziwei Huang.   

Abstract

Designing potent and selective peptides and small molecules that target Eph receptor tyrosine kinases remains a challenge and new strategies are needed for developing novel and potent ligands for these receptors. In this study, we performed a structure-activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding. To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor molecules. The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding. The most potent dimeric peptide, a SWL dimer with a 6 carbon linker, has about 13 fold increased potency compared to SWL. Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.

Entities:  

Keywords:  Eph receptors; peptide inhibitors; protein-protein interactions; structure-based drug design

Year:  2013        PMID: 24167659      PMCID: PMC3807576          DOI: 10.1021/ml3004523

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

Review 1.  EphA2-dependent molecular targeting therapy for malignant tumors.

Authors:  Rong Biao-xue; Cai Xi-guang; Yang Shuan-ying; Li Wei; Ming Zong-juan
Journal:  Curr Cancer Drug Targets       Date:  2011-11       Impact factor: 3.428

2.  Architecture of Eph receptor clusters.

Authors:  Juha P Himanen; Laila Yermekbayeva; Peter W Janes; John R Walker; Kai Xu; Lakmali Atapattu; Kanagalaghatta R Rajashankar; Anneloes Mensinga; Martin Lackmann; Dimitar B Nikolov; Sirano Dhe-Paganon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-26       Impact factor: 11.205

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

4.  Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay.

Authors:  Kumar B Pabbisetty; Xin Yue; Chen Li; Juha-Pekka Himanen; Renping Zhou; Dimitar B Nikolov; Longqin Hu
Journal:  Protein Sci       Date:  2007-03       Impact factor: 6.725

5.  Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

Authors:  Sayantan Mitra; Srinivas Duggineni; Mitchell Koolpe; Xuejun Zhu; Ziwei Huang; Elena B Pasquale
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

6.  Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.

Authors:  Dana M Brantley; Nikki Cheng; Erin J Thompson; Qing Lin; Rolf A Brekken; Philip E Thorpe; Rebecca S Muraoka; Douglas Pat Cerretti; Ambra Pozzi; Dowdy Jackson; Charles Lin; Jin Chen
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

8.  EphA2 as a promoter of melanoma tumorigenicity.

Authors:  Naira V Margaryan; Luigi Strizzi; Daniel E Abbott; Elisabeth A Seftor; M Sambasiva Rao; Mary J C Hendrix; Angela R Hess
Journal:  Cancer Biol Ther       Date:  2009-02-21       Impact factor: 4.742

9.  EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Authors:  Jeong-Won Lee; Hee Dong Han; Mian M K Shahzad; Seung Wook Kim; Lingegowda S Mangala; Alpa M Nick; Chunhua Lu; Robert R Langley; Rosemarie Schmandt; Hye-Sun Kim; Shenlan Mao; John Gooya; Christine Fazenbaker; Dowdy Jackson; David A Tice; Charles N Landen; Robert L Coleman; Anil K Sood
Journal:  J Natl Cancer Inst       Date:  2009-07-29       Impact factor: 13.506

10.  An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly.

Authors:  Elena Seiradake; Karl Harlos; Geoff Sutton; A Radu Aricescu; E Yvonne Jones
Journal:  Nat Struct Mol Biol       Date:  2010-03-14       Impact factor: 15.369

View more
  13 in total

1.  Design and synthesis of small molecule agonists of EphA2 receptor.

Authors:  Aaron Petty; Nethrie Idippily; Viharika Bobba; Werner J Geldenhuys; Bo Zhong; Bin Su; Bingcheng Wang
Journal:  Eur J Med Chem       Date:  2017-10-10       Impact factor: 6.514

2.  Dimeric small molecule agonists of EphA2 receptor inhibit glioblastoma cell growth.

Authors:  Cody M Orahoske; Yaxin Li; Aaron Petty; Fatma M Salem; Jovana Hanna; Wenjing Zhang; Bin Su; Bingcheng Wang
Journal:  Bioorg Med Chem       Date:  2020-07-25       Impact factor: 3.641

Review 3.  Eph receptors and ephrins: therapeutic opportunities.

Authors:  Antonio Barquilla; Elena B Pasquale
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-03       Impact factor: 13.820

4.  Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.

Authors:  Maricel Gomez-Soler; Marina Petersen Gehring; Bernhard C Lechtenberg; Elmer Zapata-Mercado; Kalina Hristova; Elena B Pasquale
Journal:  J Biol Chem       Date:  2019-04-23       Impact factor: 5.157

Review 5.  Targeting the Eph System with Peptides and Peptide Conjugates.

Authors:  Stefan J Riedl; Elena B Pasquale
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  A synthetic bivalent ligand of CXCR4 inhibits HIV infection.

Authors:  Yan Xu; Srinivas Duggineni; Stephen Espitia; Douglas D Richman; Jing An; Ziwei Huang
Journal:  Biochem Biophys Res Commun       Date:  2013-05-18       Impact factor: 3.575

7.  A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Authors:  Deo R Singh; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2016-06-06

8.  Pinpointed Stimulation of EphA2 Receptors via DNA-Templated Oligovalence.

Authors:  Christin Möser; Jessica S Lorenz; Martin Sajfutdinow; David M Smith
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

9.  Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.

Authors:  Parima Udompholkul; Carlo Baggio; Luca Gambini; Yu Sun; Ming Zhao; Robert M Hoffman; Maurizio Pellecchia
Journal:  Molecules       Date:  2021-06-17       Impact factor: 4.411

10.  Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

Authors:  Ahmed F Salem; Si Wang; Sandrine Billet; Jie-Fu Chen; Parima Udompholkul; Luca Gambini; Carlo Baggio; Hsian-Rong Tseng; Edwin M Posadas; Neil A Bhowmick; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2018-02-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.